Puma Biotechnology

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

Funding reportedLast round: Post-IPO Equity

BiotechnologyLos Angeles, United States

Follow Puma Biotechnology and see its new rounds in your feed.Start following

What company datasets say Puma Biotechnology raised

Funding, as reported

Reported in all$10Min dollars

Last roundPost-IPO Equity

Investors listed5

SEC Form D$165M sold, 3 filings, last Oct 2011

From Puma Biotechnology's own website and the SEC filings it signed: 10 on the team.

Heather J. BlaberSenior Vice President, Marketing
Pamela WilsonSenior Vice President, Clinical Operations
Petra RietschelSenior Vice President, Clinical Development
Roger L. StormsSenior Vice President, Sales
Douglas HuntChief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer
Gordon EsplinChief Accounting Officer
Maximo F. NouguesChief Financial Officer
Alan H. AuerbachExecutive Officer, Directori
Charles R. EylerExecutive Officeri
Richard R. PhillipsExecutive Officeri

On the board, as filediThomas R. Malley

Investors who name them

Each firm lists Puma Biotechnology on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Puma Biotechnology in front of investors. Or tell us what we have wrong.